Orforglipron + B6 3mg
Orforglipron + B6 3mg is a prescriber-directed weight-management medication option. It should be used as part of a broader care plan that includes nutrition, activity, contraindication screening, and monitoring.
This preparation combines orforglipron 3 mg — a low initiation-tier dose of the non-peptide GLP-1 receptor agonist approved by the FDA in April 2026 — with pyridoxine (vitamin B6) to minimize GI intolerance during the early phase of therapy. The 3 mg strength is intended for patients beginning or re-initiating GLP-1R agonist therapy under a prescriber-directed titration protocol. Genesis Compounding prepares this as a prescription-only, patient-specific 503A compounded oral capsule; it is not FDA-approved as a compounded preparation.
| Active Ingredient | Pharmacologic Role |
|---|---|
| Orforglipron 3 mg | Non-peptide GLP-1 receptor agonist (small molecule); low-dose initiation-tier agent that activates GLP-1R to begin appetite suppression and glycemic modulation while minimizing initial GI adverse effects. |
| Pyridoxine (Vitamin B6) — per prescriber order | B-complex vitamin with antiemetic properties; co-formulated to reduce nausea and GI discomfort commonly associated with GLP-1R agonist initiation. |
Oral capsule: Swallow intact with water, with or without food. Administer at the same time each day. As a small-molecule oral agent, orforglipron does not require fasting or limited fluid intake for effective absorption. Do not crush or chew the capsule.
The 3 mg dose is a low starting point in a titration protocol designed to allow GI adaptation before escalation.
- Initiation: 3 mg/day is typically a starting or early-step dose; the prescriber will advance the dose at 4–8 week intervals based on tolerability and clinical response.
- Pyridoxine (B6): Included to reduce nausea at initiation; prescriber-specified dose.
- Final dose, escalation schedule, and therapy duration are prescriber-determined.
- Orforglipron: Full GLP-1 receptor agonist (small molecule, non-peptide); activates GLP-1R on pancreatic beta cells (glucose-dependent insulin secretion, glucagon suppression), GI tract (delayed gastric emptying, reduced intestinal motility), and CNS (hypothalamic and brainstem satiety signaling). The small-molecule structure confers oral bioavailability without susceptibility to DPP-4 enzymatic degradation.
- Pyridoxine (B6): Essential cofactor in neurotransmitter and amino acid metabolism; reduces GI nausea via serotonergic modulation, consistent with its use as a first-line antiemetic in pregnancy-related nausea.
Indications context: The 3 mg compounded capsule is suited to the initiation phase of orforglipron therapy in adults with obesity, overweight with comorbidities, or type 2 diabetes mellitus. Starting low minimizes the GI intolerability that drives early discontinuation of GLP-1R agonist therapy across the class.
Prescriber monitoring considerations:
- Baseline weight, HbA1c, fasting glucose, renal function, lipase, and thyroid assessment where indicated.
- Follow-up at 4–8 weeks to assess GI tolerability and determine readiness for dose escalation.
- Monitor for GI-mediated dehydration and volume depletion, particularly in elderly patients.
- Review concomitant medications — gastric emptying delay may alter absorption of time-sensitive oral drugs.
Contraindications:
- Personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
- Known hypersensitivity to orforglipron or any formulation component
Warnings & Precautions:
- Thyroid C-cell tumors: class warning from rodent data; human significance not established
- Pancreatitis: suspend and evaluate if persistent severe abdominal pain occurs
- GI adverse effects: nausea most common at initiation; manage with gradual titration and supportive care
- Acute kidney injury: may occur secondary to GI fluid losses
Drug Interactions:
- Insulin/sulfonylureas: increased hypoglycemia risk
- Narrow therapeutic index oral drugs: monitor absorption changes
Common Side Effects: Nausea, mild GI discomfort, decreased appetite, and constipation. GI side effects are typically most pronounced at initiation and attenuate with continued use.
Store at controlled room temperature (20–25°C / 68–77°F), protected from light and moisture. Keep in original dispensing container, tightly closed. Do not freeze. Follow the beyond-use date assigned by Genesis Compounding as shown on the label.
Why am I starting at such a low dose (3 mg)?
Starting at a low dose is a deliberate strategy across all GLP-1R agonist therapies. Beginning low allows your GI system to adapt gradually, significantly reducing the nausea and vomiting that cause many patients to discontinue therapy. Your prescriber will escalate the dose on a schedule designed to maximize tolerability.
Will this dose help me lose weight?
At 3 mg, the primary purpose is safe initiation with GI adaptation. Meaningful weight loss typically becomes apparent at higher therapeutic doses reached during titration. The co-formulated pyridoxine helps minimize nausea so you can complete the titration schedule.
How long will I stay at 3 mg?
Typically 4–8 weeks at the starting dose before escalation, depending on tolerability and prescriber assessment. Your prescriber determines the escalation schedule.
Is it safe to take B6 daily?
Pyridoxine at the doses used as an antiemetic adjunct is well-tolerated. Very high chronic doses (>500 mg/day) are associated with sensory neuropathy, but the amounts co-formulated in this preparation are well below that threshold.
Is this FDA-approved?
Orforglipron was FDA-approved in April 2026. This compounded 3 mg + B6 capsule is a prescriber-directed, patient-specific 503A preparation by Genesis Compounding; it is not FDA-approved as a compounded product.
Clinical References
Authoritative sources reviewed in preparing this clinical summary. Provided for prescriber reference; not a substitute for the prescriber’s clinical judgment.